P662S' velocity measured by tissue Doppler imaging is more sensitive indicator of left ventricular systolic function than ejection fraction in breast cancer patients receiving tratsuzumab therapy


    loading  Checking for direct PDF access through Ovid

Abstract

Purpose: Tratsuzumab is now widely used anticancer agent to improved survival of advanced breast cancer patients. However, symptomatic heart failure is a serious side effect of tratsuzumab and anthracycline exposure is a risk factor of tratsuzumab-related cardiotoxicity.Methods: We investigated 77 breast cancer patients who were receiving tratsuzumab therapy. All patients underwent 2D and Doppler echocardiography at baseline and every 3 to 4 months thereafter.Results: Mean age was 52±9 (31-75) years. 76 (98.7%) patients were female. Tratsuzumab was used as adjuvant chemotherapy in 71 patients (92.2%). 67 patients (87.0%) had been exposured to anthracyclines [mean cumulative dose, 241.6±38.8 (200-480) mg/kg/m2]. 50 (64.9%) patients had received radiation therapy. Symptomatic CHF occurred in 1 patient (1.3%) and another 2 patients (2.6%) discontinued tratsuzumab due to decline of LV EF ≥10% without CHF symptoms. Whereas mean baseline and follow-up LV EF showed no significant change (58.8±3.8% and 58.2±5.7%, p=NS), S' velocities assessed by tissue Doppler imaging were significantly decreased (7.14±1.09 cm/s and 6.74±1.05 cm/s, p=0.002). E/E' ratio also showed trend of increase (10.3±2.7 vs.10.9±3.2, p=0.045). In patients with anthracycline exposure, these findings were consistently shown.Conclusions: The incidence of tratsuzumab-related symptomatic heart failure was low. In patients receiving tratsuzumab therapy, Doppler echocardiographic parameters including S' velocity and E/E' ratio should be assessed for surveillance of cardiac function in addition to LV EF measurement.

    loading  Loading Related Articles